Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 12/20 | 0.50 |
| ▸ | ITGAV | P06756 | 12/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.46 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235478 | 1.00 | ANPEP (0.53) | ANPEPITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL2237084 | 0.96 | ANPEP (0.48) | ANPEPITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL2237077 | 0.96 | ANPEP (0.48) | ANPEPITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL2240414 | 0.90 | CYP2D6 (0.48) | ANPEPITGB3ITGAVITGB1ITGB5 | |
| SCHEMBL2240407 | 0.90 | CYP2D6 (0.48) | ANPEPITGB3ITGAVITGB1ITGB5 | |
| Lysine SCHEMBL2473830 | 0.83 | GSR (0.49) | ANPEPITGB3ITGAVITGB1ITGB5 | |
| SCHEMBL2238476 | 0.82 | ALDH1A1 (0.46) | ANPEPPOLBKMT2ATDP1 | |
| SCHEMBL5524164 | 0.82 | ITGB3 (0.51) | ITGB3ITGAVITGB1ITGA5ITGA2B | |
| SCHEMBL2238481 | 0.82 | ALDH1A1 (0.46) | ANPEPPOLBKMT2ATDP1 | |
| SCHEMBL7148198 | 0.81 | KDM4D (0.46) | ANPEPITGB3ITGAVITGB5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637520-B2 | Template-fixed peptidomimetics with CXCR7 modulating activity | POLYPHOR AG (CH) | 2017-05-02 | — | — | US | disclosed |
| EP-2531520-B1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2016-05-11 | — | — | EP | disclosed |
| US-20150307556-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-9109009-B2 | Template-fixed peptidomimetics with CXCR7 modulating activity | POLYPHOR AG (CH) | 2015-08-18 | — | — | US | disclosed |
| US-20130225506-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2013-08-29 | — | — | US | disclosed |
| EP-2531520-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | Polyphor AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011095607-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307556-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | CXCR1, CXCL12, CXCR6 | ANPEP 226/4885ITGB3 2339/4885ITGAV 1276/4885 |
| US-20130225506-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | CXCR1, CXCL12, CXCR6 | ANPEP 196/4885ITGB3 2108/4885ITGAV 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.